The Full Wiki

More info on Paromomycin sulfate

Paromomycin sulfate: Wikis

Advertisements
  
  

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Paromomycin sulfate
Systematic (IUPAC) name
(2R,3S,4R,5R,6 S)-5-amino-6-[(1R,2S,3S,4R,6 S)-
4,6-diamino-2-[(2S,3R,4R,5R)-4-[(2 R,3R,4R,5R,6S)-
3-amino-6-(aminomethyl)-4,5-dihydroxy-oxan-2-yl]
oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-
3-hydroxy-cyclohexyl]oxy-2-(hydroxymethyl)oxane-3,4-diol
Identifiers
CAS number 1263-89-4
ATC code A07AA06
PubChem 165580
DrugBank ?
Chemical data
Formula C 23H47N5O18S 
Mol. mass 615.629 g/mol
Pharmacokinetic data
Bioavailability None
Metabolism None
Half life  ?
Excretion Fecal
Therapeutic considerations
Pregnancy cat. C(US)
Legal status Rx only U.S.
Routes Oral, intramuscular

Paromomycin sulfate (synonyms: monomycin, aminosidine[1]; brand name Humatin) is an aminoglycoside antibiotic, first isolated from Streptomyces krestomuceticus in 1950s.[2]

Contents

Uses

It is an antibiotic designed to fight intestinal infections such as cryptosporidiosis,[3] amoebiasis,[4] and leishmaniasis.[5]

The route of administration is intramuscular injection.

Mechanism

Paromomycin inhibits protein synthesis by binding to 16S ribosomal RNA.[6]

History and availability

Monomycin was demonstrated to be effective against cutaneous leishmaniasis in clinical studies in the USSR in the 1960s, and in trials with visceral leishmaniasis in early 1990s.[1]

It was developed as a therapeutic against visceral leishmaniasis by the Institute for OneWorld Health. Paromomycin was granted orphan drug status in 2005[7] and was approved by the Drug Controller General of India in September 2006 for treatment of visceral leishmaniasis.[8]

As of February 5th, 2008, King Pharmaceuticals is discontinuing the sale of Humatin, Paromomycin continues to be available in the United States from another manufacturer.[9]

References

  1. ^ a b Neal R.A. et al. (1994). "Aminosidine ointments for the treatment of experimental cutaneous leishmaniasis". Transactions of the Royal Society of Tropical Medicine and Hygiene 88 (2): 223–5. doi:10.1016/0035-9203(94)90307-7.  
  2. ^ Davidson R.N., den Boer M., Ritmeijer K. (2008). "Paromomycin". Transactions of the Royal Society of Tropical Medicine and Hygiene. doi:10.1016/j.trstmh.2008.09.008.  
  3. ^ Sweetman S.C. (Editor). (2002). Martindale: the complete drug reference. 33rd ed. London: Pharmaceutical Press
  4. ^ paromomycin at Dorland's Medical Dictionary
  5. ^ Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK (June 2007). "Injectable paromomycin for visceral leishmaniasis in India". N. Engl. J. Med. 356 (25): 2571–81. doi:10.1056/NEJMoa066536. PMID 17582067. http://content.nejm.org/cgi/pmidlookup?view=short&pmid=17582067&promo=ONFLNS19.  
  6. ^ Vicens, Quentin; Eric Westhof (August 2001). "Crystal Structure of Paromomycin Docked into the Eubacterial Ribosomal Decoding A Site". Structure 9 (8): 647–658. doi:10.1016/S0969-2126(01)00629-3. PMID 11587639. http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VSR-43VBX2W-C&_user=10&_coverDate=08%2F31%2F2001&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=1b1e19d11ca34e14eca1603c2be009d5. Retrieved 2007-02-10.  
  7. ^ Institute for OneWorld Health (23 May 2005). "Institute for OneWorld Health Drug Receives “Orphan” Designation From U.S. and European Regulatory Agencies". Press release. http://www.oneworldhealth.org/media/details.php?prID=115. Retrieved 2007-02-10.  
  8. ^ Institute for OneWorld Health (8 September 2006). "New cure for deadly visceral leishmaniasis (kala-azar) approved by government of India". Press release. http://www.oneworldhealth.org/media/details.php?prID=154. Retrieved 2007-02-10.  
  9. ^ humatin_king.pdf at fda.gov
Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message